Co-Diagnostics, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Co-Diagnostics, Inc. (NASDAQ: CODX) develops, manufactures, and markets molecular diagnostics technologies utilizing nucleic acid detection and analysis (DNA or RNA); its proprietary Co-Primers technology enables multiplex PCR testing with innovations in color chemistry and melting analysis for infectious diseases, genetic markers, and other applications. The company offers a portfolio of real-time PCR reagents and tests including Logix Smart COVID-19 (RUO), Logix Smart Monkeypox (RUO), Logix Smart Mpox (2-Gene) (RUO), Logix Smart SARS-CoV-2 (Genes RdRp/E) (RUO), Logix Smart ABC (RUO), STD Panel, HCV RNA Real-time PCR Kit, HIV RNA Real-time PCR Kit, Tuberculosis (TB), Zika, hepatitis B and C, Malaria, dengue, EIKON PCR, LightPCR, Liquid Biopsy Test for cancer screening, and ABC Test; it also provides the Co-Dx PCR platform comprising the Co-Dx PCR Pro instrument, diagnostic test cup system, MDx device, lab systems, point-of-care and at-home devices like Co-Dx PCR Home and Co-Dx Box, and associated mobile applications for rapid results in approximately 30 minutes. Founded in 2013 and headquartered in Salt Lake City, Utah, with an address at 2401 S Foothill Dr Suite D, the company targets healthcare providers, diagnostic labs, consumers, point-of-care facilities, food safety sectors, and international markets through operations focused on democratizing accessible, low-cost molecular testing globally. In recent developments, Co-Diagnostics established Comira Diagnostics as a joint venture with Arabian Eagle Manufacturing to localize and distribute diagnostics in Saudi Arabia and 18 additional MENA countries; formed Kocera Diagnostics as its Indian joint venture, engaging Maxim Group LLC as exclusive financial advisor to explore strategic alternatives including a potential SPAC transaction; and received an NIH RadixTech grant to advance diagnostic innovations.
Company News
Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
Head to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX)
Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week
Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026
Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript
Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
Co-Diagnostics to Hold Press Conference
Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida
Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event
Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript
Co-Diagnostics Reports Second Quarter 2026 Financial Results
Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast